Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A phase II study of gemcitabine in patients with malignant pleural mesothelioma
Autore:
van Meerbeeck, JP; Bass, P; Debruyne, C; Groen, HJ; Manegold, C; Ardizzoni, A; Gridelli, C; van Marck, EA; Lentz, M; Giaccone, G;
Indirizzi:
Univ Hosp, Dept Pulmonol, NL-3000 CA Rotterdam, Netherlands Univ Hosp Rotterdam Netherlands NL-3000 CA 000 CA Rotterdam, Netherlands Univ Hosp Antwerpen, Edegem, Belgium Univ Hosp Antwerpen Edegem BelgiumUniv Hosp Antwerpen, Edegem, Belgium Netherlands Canc Inst, Amsterdam, Netherlands Netherlands Canc Inst Amsterdam Netherlands nst, Amsterdam, Netherlands European Org Res Treatment Canc, Ctr Data, Brussels, Belgium European Org Res Treatment Canc Brussels Belgium ata, Brussels, Belgium Univ Hosp, Groningen, Netherlands Univ Hosp Groningen NetherlandsUniv Hosp, Groningen, Netherlands Thoraxklin LVA Baden, Heidelberg, Germany Thoraxklin LVA Baden Heidelberg Germany LVA Baden, Heidelberg, Germany Ist Nazl Ric Cancro, Genoa, Italy Ist Nazl Ric Cancro Genoa ItalyIst Nazl Ric Cancro, Genoa, Italy Ist Nazl Tumori, Naples, Italy Ist Nazl Tumori Naples ItalyIst Nazl Tumori, Naples, Italy Free Univ Amsterdam Hosp, Amsterdam, Netherlands Free Univ Amsterdam HospAmsterdam Netherlands , Amsterdam, Netherlands
Titolo Testata:
CANCER
fascicolo: 12, volume: 85, anno: 1999,
pagine: 2577 - 2582
SICI:
0008-543X(19990615)85:12<2577:APISOG>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
CANCER COOPERATIVE GROUP; CELL LUNG-CANCER; LEUKEMIA GROUP-B; CLINICAL-TRIALS; CISPLATIN; CHEMOTHERAPY; EFFICACY; SAFETY;
Keywords:
malignant mesothelioma; chemotherapy; Phase II study; gemcitabine; pleura; hemolytic-uremic syndrome;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
25
Recensione:
Indirizzi per estratti:
Indirizzo: van Meerbeeck, JP Univ Hosp, Dept Pulmonol, POB 2040, NL-3000 CA Rotterdam, Netherlands Univ Hosp POB 2040 Rotterdam Netherlands NL-3000 CA nds
Citazione:
J.P. van Meerbeeck et al., "A phase II study of gemcitabine in patients with malignant pleural mesothelioma", CANCER, 85(12), 1999, pp. 2577-2582

Abstract

BACKGROUND, Gemcitabine has shown activity in patients with less chemosensitive solid tumors. Phase II screening of novel drugs is an accepted methodwith which to investigate new therapies in malignant mesothelioma. The European Organization for Research and Treatment of Cancer-Lung Cancer Cooperative Group has performed several sequential Phase II trials of new agents for the treatment of mesothelioma over the last 10 years. METHODS. Twenty-seven chemotherapy-naive patients with histologically proven malignant mesothelioma were treated with gemcitabine as a 30-minute intravenous administration of 1250 mg/m(2) on Days 1, 8, and 15 of a 28-day cycle. Therapy continued for up to ten cycles unless disease progression or excessive toxicity mandated discontinuation. RESULTS, With a median relative dose intensity of 96%, toxicity was mild and neutropenia of greater than or equal to Grade 3 (according to National Cancer Institute criteria) occurred in 30% of patients, without episodes of febrile neutropenia. One case of hemolytic-uremic syndrome, most likely related to gemcitabine use, was observed. Overall, 2 objective responses were observed (response rate of 7%; 95% confidence interval, 1-24%). The median survival was 8 months. CONCLUSIONS. At the prescribed dosage and schedule, single agent gemcitabine appears to have limited activity in chemotherapy-naive patients with malignant pleural mesothelioma. Cancer 1999;85:2577-82. (C) 1999 American Cancer Society.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/04/20 alle ore 19:52:27